[Teicoplanin in the treatment of XXXX due to methicillin resistant staphylococci. Experience in adult patients].

@entity6275 @entity3256 @entity5414 @entity79 @entity11248 @entity1104
We retrospectively evaluated 89 episodes of @entity79 due to @entity3256 -resistant staphylococci: 56 @entity6275 ( @entity6275 ), 10 @entity5414 ( @entity5414 ) and 23 infections associated to arthroplasties (IAA). We analyzed the efficacy of @entity11248 (T) in three times a week or daily administration schemes and @entity1104 ( @entity1104 ). Also, we determined cost savings derived from outpatient parenteral antibiotic therapy (OPAT). The overall efficacy of T in @entity6275 and both in cases with and without implants, was higher when antibiotic therapy was associated to @entity1104 (86 vs. 46%, p = 0.001; 100 vs. 33%, p = 0.0049 and 76 vs. 50%, p = 0.09). All @entity5414 were cured. The overall efficacy of T was higher in IAA with implant removal vs. surgical debridement (100 vs. 54%, p = 0.045). In all cases, T was similarly effective when administered three times a week vs. daily administration, when associated to @entity1104 . The savings derived from OPAT were 897 days/bed and USS 179,400. Adverse effects were few and light (8 episodes, 9%). The results obtained are similar to those published in the literature and show that T administered daily or in a three times a week scheme and associated to @entity1104 , is effective and safe for the treatment of @entity79 . The savings derived from OPAT, mainly related to reduced hospitalization, are significant in these pathologies, which usually require long treatment periods.
